Madrigal Pharmaceuticals ...

315.10
-26.17 (-7.67%)
At close: Mar 03, 2025, 3:59 PM
313.47
-0.52%
After-hours: Mar 03, 2025, 04:17 PM EST

Madrigal Pharmaceuticals Statistics

Share Statistics

Madrigal Pharmaceuticals has 21.81M shares outstanding. The number of shares has increased by 9.61% in one year.

Shares Outstanding 21.81M
Shares Change (YoY) 9.61%
Shares Change (QoQ) 0.45%
Owned by Institutions (%) 99.99%
Shares Floating 18.61M
Failed to Deliver (FTD) Shares 9
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 4.08M, so 18.72% of the outstanding shares have been sold short.

Short Interest 4.08M
Short % of Shares Out 18.72%
Short % of Float 22.21%
Short Ratio (days to cover) 10.54

Valuation Ratios

The PE ratio is -14.09 and the forward PE ratio is -24.13. Madrigal Pharmaceuticals's PEG ratio is -1.47.

PE Ratio -14.09
Forward PE -24.13
PS Ratio 36.44
Forward PS 1.8
PB Ratio 8.7
P/FCF Ratio -14.36
PEG Ratio -1.47
Financial Ratio History

Enterprise Valuation

Madrigal Pharmaceuticals Inc. has an Enterprise Value (EV) of 4.34B.

EV / Earnings -9.32
EV / Sales 24.1
EV / EBITDA -8.72
EV / EBIT -8.72
EV / FCF -9.5

Financial Position

The company has a current ratio of 6.1, with a Debt / Equity ratio of 0.

Current Ratio 6.1
Quick Ratio 5.9
Debt / Equity 0
Total Debt / Capitalization 0.13
Cash Flow / Debt -463.45
Interest Coverage 33.94

Financial Efficiency

Return on equity (ROE) is -0.62% and return on capital (ROIC) is -65.91%.

Return on Equity (ROE) -0.62%
Return on Assets (ROA) -0.45%
Return on Capital (ROIC) -65.91%
Revenue Per Employee $341,160.98
Profits Per Employee $-882,371.21
Employee Count 528
Asset Turnover 0.17
Inventory Turnover 0.18

Taxes

Income Tax 0
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by 35.82% in the last 52 weeks. The beta is -0.38, so Madrigal Pharmaceuticals's price volatility has been lower than the market average.

Beta -0.38
52-Week Price Change 35.82%
50-Day Moving Average 321.47
200-Day Moving Average 276.61
Relative Strength Index (RSI) 53.03
Average Volume (20 Days) 413.37K

Income Statement

In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M and earned -465.89M in profits. Earnings per share was -21.9.

Revenue 180.13M
Gross Profit 173.9M
Operating Income -497.88M
Net Income -465.89M
EBITDA -497.88M
EBIT -497.88M
Earnings Per Share (EPS) -21.9
Full Income Statement

Balance Sheet

The company has 100.02M in cash and 983K in debt, giving a net cash position of 99.04M.

Cash & Cash Equivalents 100.02M
Total Debt 983K
Net Cash 99.04M
Retained Earnings -1.8B
Total Assets 1.07B
Working Capital 885.82M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -455.57M and capital expenditures -1.46M, giving a free cash flow of -457.03M.

Operating Cash Flow -455.57M
Capital Expenditures -1.46M
Free Cash Flow -457.03M
FCF Per Share -21.48
Full Cash Flow Statement

Margins

Gross margin is 96.54%, with operating and profit margins of -276.39% and -258.64%.

Gross Margin 96.54%
Operating Margin -276.39%
Pretax Margin -258.64%
Profit Margin -258.64%
EBITDA Margin -276.39%
EBIT Margin -276.39%
FCF Margin -253.72%

Dividends & Yields

MDGL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -6.41%
FCF Yield -6.13%
Dividend Details

Analyst Forecast

The average price target for MDGL is $383.5, which is 12.2% higher than the current price. The consensus rating is "Buy".

Price Target $383.5
Price Target Difference 12.2%
Analyst Consensus Buy
Analyst Count 13
Stock Forecasts

Stock Splits

The last stock split was on Jul 25, 2016. It was a backward split with a ratio of 1:35.

Last Split Date Jul 25, 2016
Split Type backward
Split Ratio 1:35

Scores

Altman Z-Score 12.97
Piotroski F-Score 4